Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit: reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: (WFRF:(Larsson N)) srt2:(1995-1999) > Inhibition of compl...

Larsson, R (författare)

Inhibition of complement activation by soluble recombinant CR1 under conditions resembling those in a cardiopulmonary circuit : reduced up-regulation of CD11b and complete abrogation of binding of PMNs to the biomaterial surface.

Artikel/kapitelEngelska1997

Förlag, utgivningsår, omfång ...

1997
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:uu-266927
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-266927URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

The influence of soluble recombinant CR1 (sCR1) on complement activation, and its indirect effects on the coagulation system and cellular responses were assessed in two models for the study of blood/surface and blood/air interactions, as are encountered in e.g. cardiopulmonary bypass circuits. The concentrations of C3a and sC5b-9 and the amount of bound C3/C3 fragments were analyzed as indicators of complement activation. Thrombin-antithrombin complexes, the platelet count, surface-ATP, beta-thromboglobulin, and the expression of CD11b on leukocytes were the parameters analyzed to reflect coagulation and cellular responses. In addition, immunochemical analyses of the phenotypes of surface-bound leukocytes and platelets were performed. Recombinant sCR1, at doses ranging between 0.1-0.25 mg/ml, was found to completely inhibit the generation of sC5b-9, and of C3a by two thirds; the binding of C3 and/or C3 fragments to the surface was almost entirely abolished. As a result of the inhibition of complement activation, the expression of CD11b on PMNs, and the binding of these cells to the biomaterial surface was almost completely lost. In contrast, the thrombin-antithrombin complexes, the platelet count, and the adherence of platelets to the surface, as reflected by the ATP binding and the release of beta-thromboglobulin, were not affected. These data show that complement activation, in association with extra-corporeal treatment, causes activation and binding of PMNs to the biomaterial and that these effects can be completely abolished by the addition of soluble recombinant sCR1.

Biuppslag (personer, institutioner, konferenser, titlar ...)

Elgue, G (författare)
Larsson, A (författare)
Ekdahl, K NUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi (författare)
Nilsson, U RUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi (författare)
Nilsson, BUppsala universitet,Institutionen för onkologi, radiologi och klinisk immunologi (författare)
Uppsala universitetInstitutionen för onkologi, radiologi och klinisk immunologi (creator_code:org_t)

Sammanhörande titlar

Ingår i:Immunopharmacology38:1-2, s. 119-1270162-31091879-047X

Internetlänk

https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-266927

Hitta via bibliotek

Immunopharmacology (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Larsson, R; Elgue, G; Larsson, A; Ekdahl, K N; Nilsson, U R; Nilsson, B

Artiklar i publikationen: Immunopharmacolo ...

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se